BC Platforms Enlists TripleBlind for AI Data Protection

NEW YORK – BC Platforms said Tuesday that has formed a partnership with enterprise data privacy company TripleBlind to build a privacy-preserving, federated layer of artificial intelligence for the firm’s BCRquest.com global network of biobanks.

TripleBlind Welcomes Gaurav Satam as Vice President of Corporate Development, Furthering Initiatives in Ethical Data Sharing in Healthcare

We are pleased to announce that Gaurav Satam has joined TripleBlind as its new Vice President of Corporate Development. Satam is responsible for TripleBlind’s Healthcare business in his new role with the company. 

“We have taken exceptional measures to focus on creating a safer and more ethical sphere for data sharing in healthcare, including achieving HIPAA compliance earlier this year,” said TripleBlind CEO, Riddhiman Das. “Under guidance from Gaurav, we hope to further communicate our capabilities in healthcare, and amplify TripleBlind’s solution to improve what is currently considered state-of-the-art in the industry.”

Satam has more than 13 years of experience in corporate strategy and business development for healthcare companies. Prior to joining TripleBlind, he worked for Mayo Clinic Ventures, a healthcare data analytics company called Inovalon and St. Jude Medical. Satam specializes in corporate venture, strategic development, finance, research and development, and product management roles. 

Gaurav Satam: VP, Corporate Development

“I am looking forward to using my unique skill set to further TripleBlind’s vision of data privacy in the healthcare industry,” said Satam. “Although my background is primarily in healthcare, I join the TripleBlind team ready to offer this solution to all industries and companies that value finding a better way to share data.”

TripleBlind Expands Collaboration with and Receives Investment from Mayo Clinic

On the heels of announcing the close of $8.2 million in seed funding, led by Dolby Family Ventures, TripleBlind is pleased to announce that it has expanded its collaboration with Mayo Clinic. The renowned academic medical center invested in a seed extension round and was the only investor participating.

TripleBlind is collaborating with Mayo Clinic on data-analysis, algorithm training and validation on one-way encrypted data and on next generation algorithm sharing. TripleBlind’s API-driven virtual exchange solution allows Mayo Clinic researchers to validate interoperability of encrypted algorithms on encrypted data and train new algorithms on private data.

 “As part of our mission to commercialize innovative technologies for the benefit of patients worldwide, we are furthering our collaboration with TripleBlind through this investment,” said Andy Danielsen, Chair, Mayo Clinic Ventures.

Mayo Clinic joins Dolby Family Ventures, Accenture Ventures, Okta Ventures, NextGen Venture Partners, Operator Partners, Wavemaker Three-Sixty Health, AVG Basecamp Fund, Anorak Ventures, Quiet Capital, Clocktower Technology Ventures, Parity Responsible Technology Fund and Manresa Ventures as a TripleBlind investor.

Through TripleBlind’s solution, organizations can share data and collaborate without decrypting the data, enforcing  HIPAA and other data standards, and create more ethical consumer and patient profiles. 

TripleBlind Receives Investment from Mayo Clinic, Expanding Current Collaboration

KANSAS CITY, Mo., April 27, 2021 (GLOBE NEWSWIRE) — Today, TripleBlind announced that it expanded its collaboration with Mayo Clinic, which invested in a seed extension round, the only investor participating. TripleBlind recently announced that it raised $8.2 million in a significantly oversubscribed seed funding round. Mayo Clinic joins Accenture Ventures, Okta Ventures, NextGen Venture Partners, Operator Partners, Wavemaker Three-Sixty Health, AVG Basecamp Fund, Anorak Ventures, Quiet Capital, Clocktower Technology Ventures, Parity Responsible Technology Fund and Manresa Ventures as a TripleBlind investor.

“As part of our mission to commercialize innovative technologies for the benefit of patients worldwide, we are furthering our collaboration with TripleBlind through this investment,” said Andy Danielsen, Chair, Mayo Clinic Ventures.

TripleBlind is collaborating with Mayo Clinic on data-analysis, algorithm training and validation on one-way encrypted data and on next generation algorithm sharing. Mayo Clinic researchers are using TripleBlind’s tools to validate interoperability of encrypted algorithms on encrypted data and the training of new algorithms on private data.

TripleBlind’s API-driven virtual exchange solution is based on breakthroughs in advanced mathematics, which the Mayo Clinic team is using and validating. TripleBlind is not accessing any Mayo Clinic data.

“TripleBlind’s API-driven virtual exchange solution accelerates how organizations develop, test and deploy AI solutions in healthcare, and leverage third party data amidst heavily regulated privacy concerns,” said Riddhiman Das, co-founder and CEO of TripleBlind. “We believe Mayo Clinic’s investment further supports our approach and we’re excited to continue our collaboration to deploy TripleBlind’s encryption tools and work on real-world applications.”

TripleBlind’s solution functions as the innovative data encryption conduit that keeps the data and intellectual property in the algorithm secure and addresses the issue that today, healthcare systems have to either transfer data or algorithms outside their institution for experts to train or conduct research. The encryption conduit Mayo Clinic is evaluating will eliminate the need for data transfer or for sharing the algorithm, thus protecting intellectual property and data.

The collaboration is also seeking to demonstrate that TripleBlind’s toolset can be applied to train and develop entirely new algorithms from independent entities anywhere in the world without the need to share raw data, thus preserving privacy and security while meeting regulatory standards.

 

About TripleBlind

TripleBlind’s patented breakthroughs in advanced mathematics arm organizations with the ability to share, leverage and monetize regulated data, such as PII and PHI, and mission-critical enterprise data, such as tax returns and banking transactions. It unlocks the estimated 105 petabytes of data stored by enterprises today that are inaccessible and unmonetized due to privacy concerns and regulations. With TripleBlind, decision-makers generate new revenue for their organizations by gaining deeper insights faster, creating improved modeling and analysis, and collaborating more effectively with customers and partners and even competitors, while enabling enterprises to enforce today’s regulatory standards, such as HIPAA, GDPR and PDPA.

For more information, please visit tripleblind.ai.

 

Contact information:

Victoria Guimarin
UPRAISE Marketing + Public Relations for TripleBlind
Tel: +1 (415) 397-7600
tripleblind@upraisepr.com

 

 

TripleBlind Accelerates Secure Data Sharing within BC Platforms’ Global Healthcare Data Network

Healthcare is ripe for a change with data availability and new data analysis techniques, including the rise of AI and machine learning. As companies look to work with healthcare “data owners” to innovate and improve patient care, they need to ensure no compromises are made with patient data in the face of new threats and vulnerabilities.

lab workers

TripleBlind’s recently announced strategic partnership with BC Platforms is a prime example of how our next-generation data privacy technology enables companies to safely provide and consume sensitive data without compromising privacy or security. TripleBlind’s tools will empower BC Platforms, a global leader in providing robust data for personalized medicine, to ensure data always remains encrypted throughout the process with no decryption possible, which is better than the current gold standard of homomorphic encryption or secure computing. BC Platforms’ global genomic and clinical database network of customers and data provider partners from the E.U., U.S., and Asia will leverage TripleBlind’s fastest and most secure privacy framework.TripleBlind’s ability to operate on any type of data such as images, text, voice, video, tabular data and genomic and perform any data operations, including training, AI algorithms, along with digital rights management, will give confidence to all parties involved in the transaction. This type of flexibility and scalability will allow for rapid innovation among BC Platforms’ collaborators to improve the quality of care and reduce cost. Interoperability across organizations using different hardware and cloud providers has been a significant obstacle in broader collaboration among companies and institutes worldwide. Also, data privacy regulations like GDPR, CCPA, HIPAA and data residency laws that change with location add complexity to partner with others and limit innovation at a global scale. Companies like BC Platforms can now use TripleBlind technology without worrying about interoperability issues and at the same time comply with not only GDPR, CCPA, HIPAA but also stricter regulation of data residency.

Enormous data availability has changed the way institutes operate and leverage data in any industry, but healthcare remains the one with the most potential and the most complexities. It is important to acknowledge no matter the potential of the data to improve human life, it is also important to acknowledge that organizations must create an environment which is secure, trusted and scalable for data sharing. As we work with companies like BC Platforms and other players in the provider, payer, pharma, and medical devices markets, we are hopeful about the future where healthcare innovation can happen while preserving and respecting patient privacy. 

 

About BC Platforms

BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine, accelerating the translation of insights into clinical practice. Our technology drives the infinite loop between personalized care and research discoveries, leveraging the latest science, deep technical expertise, strategic partnerships, and harmonized, diverse data collections. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. Additionally, BC Platforms has developed a Global Data Partner Network BCRQUEST.com, which provides genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms’ vision is to build the world’s leading analytics platform for healthcare and industry, providing access to diverse genomic and clinical data and samples from more than 5 million subjects, consolidated from a global network of Data Partners. 

Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by over 20 years of working in close collaboration with a network of leading researchers, developers, and industry partners. BC Platforms has global operations with its headquarters in Zurich, Switzerland, research and development in Espoo, Finland, and presence in London, Boston and in Singapore.

 

 

About the Author

Gaurav Satam, VP, Corporate Development, has more than 13 years of experience working in the healthcare industry. Prior to joining TripleBlind, he worked for Mayo Clinic Ventures, Inovalon, a healthcare data analytics company and St. Jude in the Medical, where he worked in corporate venture, strategic development, finance, R&D, and product management roles.

BC Platforms Partners with TripleBlind to Power Federated Artificial Intelligence (AI) Data Privacy Approaches

Supporting BCP’s contribution to €6.5 million Finnish-led PRIVASA project

20 April 2021 – Zurich, Switzerland and Espoo, Finland – BC Platforms (BCP), a global leader in healthcare data management, analytics and access, announced a new strategic partnership with US-based company TripleBlind  to help drive the development of privacy and intellectual property rights (IPR) preserving “federated AI” for its BCRQUEST.com Global Data Partner Network. The partnership will enhance BCP’s contribution to the Finnish-led PRIVASA (Privacy Preserving AI for Synthetic and Anonymous Health Data) consortium, which recently received EUR €6.5 million in funding by Business Finland to develop methods for the safe utilization of sensitive data.

The two-year PRIVASA project aims to promote access to, and sharing of, anonymised health data to accelerate product development by Finnish health technology companies operating in international markets. BCP will be contributing federated AI learning approaches to train machine learning algorithms without the need to exchange actual data. This method will enable BCP to address data governance and privacy requirements, as individual-level data never needs to leave its institution of origin. BCP’s partnership with TripleBlind will further improve this federated AI concept by ensuring IPR protection, encrypting analyses and results using its proprietary cryptographic technology.

Timo Kanninen, CSO and Founder of BC Platforms, said, “In partnership with TripleBlind, our new federated AI learning platform, which is based upon data from BCRQUEST’s global genomic and clinical database network, could significantly speed up research and development without compromising on patient privacy or IPR. AI has the potential to transform healthcare from a “one-size-fits-all” medicine approach to a personalized one, where individual treatment plans can be tailored for each patient, leading to an improved quality of care and significant cost savings.”

Riddhiman Das, CEO and Co-Founder of TripleBlind, said, “We are excited to be partnering with BCP, coupling our next-generation private data sharing  technology with BCRQUEST’s data network for use in research environments with strict regulatory standards including GDPR, CCPA, and HIPAA. We look forward to enabling the network to share and collaborate with the vast amount of data that today is unaccessible and uncommercialized due to regulatory concerns. By improving privacy, we will enable the use of richer, more diverse third-party clinical and genomic datasets, facilitating the development of more accurate and less biased novel AI-based models.”

BC Platforms is one of the key corporate partners in the PRIVASA consortium, alongside the University of Turku, the Finnish Institute for Health and Welfare (THL) as well as a number of notable industry partners including Bayer, Fujitsu Finland, MVision, PerkinElmer and Polar Electro.

 

About BC Platforms

BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine, accelerating the translation of insights into clinical practice. Our technology drives the infinite loop between personalized care and research discoveries, leveraging latest science, deep technical expertise, strategic partnerships, and harmonized, diverse data collections. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. Additionally, BC Platforms has developed a Global Data Partner Network BCRQUEST.com, which provides genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms’ vision is to build the world’s leading analytics platform for healthcare and industry, providing access to diverse genomic and clinical data and samples from more than 5 million subjects, consolidated from a global network of Data Partners.

Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by over 20 years of working in close collaboration with a network of leading researchers, developers, and industry partners. BC Platforms has global operations with its headquarters in Zurich, Switzerland, research and development in Espoo, Finland, and presence in London, Boston and in Singapore.  For more information, please visit www.bcplatforms.com or follow us on LinkedIn @BC Platforms.

 

About TripleBlind

Vast amounts of data stored by enterprises today are inaccessible and not commercialized due to privacy concerns, operational complexity and regulation. TripleBlind’s patented breakthroughs in advanced mathematics arm organizations with the ability to share, leverage and commercialize  regulated data, such as PII and PHI, and mission-critical enterprise data, such as tax returns and banking transactions. It unlocks the estimated 105 petabytes of data stored by enterprises today, creating new revenue opportunities while controlling data usage and automatically enforcing compliance with GDPR, HIPAA and other privacy regulations. For more information, visit tripleblind.ai.

 

Contact information:

Tero Silvola
BC Platforms AG
Tel: + 358 40 590 5733
Tero.silvola@bcplatforms.com

 

Katja Stout
Scius Communications
Tel: +44 7789435990
katja@sciuscommunications.com

 

Victoria Guimarin
UPRAISE Marketing + Public Relations for TripleBlind
Tel: +1 (415) 397-7600
tripleblind@upraisepr.com